Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer
Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer
Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer
Submitted by
admin
on November 1, 2018 - 10:29am
Source:
CP Wire
News Tags:
Bio-Thera Solutions
HER2-positive metastatic breast cancer
BAT8001
China
Headline:
Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer
snippet:
BAT8001 is also being studied gastric cancers
Bio-Thera recently announced that is BLA for a Humira biosimilar had been accepted for review in China
The company is also developing a biosimilar to Actemra
Do Not Allow Advertisers to Use My Personal information
